Lv61
1990 积分 2022-07-12 加入
Treatment of Allergic Conjunctivitis: Results of a 1-Month, Single-Masked Randomized Study
13天前
已完结
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
27天前
已完结
JACQLQ subjective symptom questionnaire score and clinical test results for patients with allergic conjunctival disease
28天前
已完结
Allergen immunotherapy: A practice parameter third update
1个月前
已完结
Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge
1个月前
已完结
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
1个月前
已完结
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
1个月前
已完结
Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients
1个月前
已完结
Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial
1个月前
已完结
A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children
1个月前
已完结
皖公网安备34019202002308
